HCA Healthcare (HCA) insider buying and selling
Every Table I transaction reported by directors and officers of S&P 500 companies on SEC Form 4 filings (2 business days to file): each row labeled with its official transaction code, nothing filtered out beforehand.
Open-market purchases (code P) are the rare signal, in green; sales (code S) are common and often pre-scheduled (10b5-1). Table II (derivatives) is not included: its prices are exercise prices, not market values. Guide: insider buying.
| Date | Ticker | Insider | Role | Shares | Price | Amount | % of stake | Type / filing |
|---|
Download these transactions as CSV No account, no sign-up. The data is public: it comes from SEC Form 4 filings.
HCA Healthcare, Inc. (HCA) insider buying and selling: no purchases, 7 sales
66 Form 4 Table I transactions filed with the SEC by HCA Healthcare, Inc. insiders between 2025-09-08 and 2026-08-28 (15-month history): 0 open-market purchases and 7 sales, plus 59 transactions under other Form 4 codes, broken down one by one below. The largest open-market trade is a sale of $21.5M by Hazen Samuel N on 2026-02-03.
HCA Healthcare insider buying and selling over the last 12 months
Between Oct 21, 2025 and Oct 20, 2026, HCA Healthcare insiders filed 6 sales worth $31.1M on the open market, and no purchases.
The biggest seller was Hazen Samuel N (CEO): $21.5M in 1 sale, out of 5 different sellers.
The largest trade of the period was a sale of $21.5M on Feb 3, 2026, by Hazen Samuel N (CEO). Form 4 on sec.gov (0001193125-26-039805).
None of the 6 sales carries the 10b5-1 plan flag on the Form 4 (sales scheduled months ahead).
The latest sale from Feb 18, 2026.
Against its sector (Healthcare, 59 companies with an insider page on this site), over the same dates the median is 9 sales and 0 purchases on the open market. HCA Healthcare has more sales than 21 of the other 58, ranks 22 of 59 by net dollars sold, and 19 of the 59 have at least one purchase.
The 20 most important trades
With no open-market purchases, the table starts with HCA's sales, largest first. The full history is in the tool above, already searched.
See all 66 HCA trades in the full history →
| Trade date | Filed | Insider | Role | Amount | Code | Filing |
|---|---|---|---|---|---|---|
| 2026-02-03 | 2026-02-05 | Hazen Samuel N | CEO | $21.5M | S — Open-market sale7 Form 4 footnotesF1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $502.49 to $503.485, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $501.485 to $502.455, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $500.44 to $501.425, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $499.47 to $500.425, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $498.41 to $499.395, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $497.49 to $498.385, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $497.10 to $497.38, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. | SEC |
| 2026-02-11 | 2026-02-12 | Berres Jennifer | SVP & Chief Human Res. Officer | $4.1M | S — Open-market saleForm 4 footnoteF2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $525.97to $526.3101, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. | SEC |
| 2026-02-11 | 2026-02-12 | Wyatt Christopher F. | SVP & Controller | $2.0M | S — Open-market sale | SEC |
| 2025-11-05 | 2025-11-05 | Mcalevey Michael R | EVP & Chief Legal & Admin Off. | $1.8M | S — Open-market sale | SEC |
| 2025-09-08 | 2025-09-08 | Cuffe Michael S. | EVP and Chief Clinical Officer | $1.6M | S — Open-market sale (scheduled 10b5-1)2 Form 4 footnotesF1 The exercise of stock appreciation rights and sale of shares reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 6, 2025. F2 Includes 2,595.9017 shares acquired under the Issuer's employee stock purchase plans. | SEC |
| 2026-02-18 | 2026-02-18 | Mcalevey Michael R | EVP & Chief Legal & Admin Off. | $904k | S — Open-market sale | SEC |
| 2026-02-03 | 2026-02-05 | Cuffe Michael S. | EVP and Chief Clinical Officer | $747k | S — Open-market sale | SEC |
| 2026-01-30 | 2026-02-02 | Hazen Samuel N | CEO | $20.3M | F — Tax withholding (shares surrendered for taxes) | SEC |
| 2025-10-31 | 2025-11-04 | Hazen Samuel N | CEO | $13.0M | F — Tax withholding (shares surrendered for taxes) | SEC |
| 2026-02-10 | 2026-02-12 | Hazen Samuel N | CEO | $10.7M | F — Tax withholding (shares surrendered for taxes) | SEC |
| 2026-02-05 | 2026-02-09 | Foster Jon M | EVP and COO | $8.3M | F — Tax withholding (shares surrendered for taxes) | SEC |
| 2026-01-30 | 2026-02-02 | Hazen Samuel N | CEO | $6.9M | M — Option exercise | SEC |
| 2025-11-03 | 2025-11-05 | Mcalevey Michael R | EVP & Chief Legal & Admin Off. | $4.3M | F — Tax withholding (shares surrendered for taxes) | SEC |
| 2026-02-05 | 2026-02-09 | Foster Jon M | EVP and COO | $4.1M | M — Option exercise | SEC |
| 2025-10-31 | 2025-11-04 | Hazen Samuel N | CEO | $4.0M | M — Option exercise | SEC |
| 2026-08-26 | 2026-08-28 | Mcalevey Michael R | EVP & Chief Legal & Admin Off. | $3.3M | J — Other transaction (explained in the filing) Indirect holding, through: By 2026 GRAT Form 4 footnoteF1 Pursuant to a power of substitution, on August 26, 2026, the Reporting Person transferred 7,769 shares of common stock of the Issuer from a trust to direct ownership in exchange for assets of equal value. The transfer was made at a price per share equal to $429.00 (the average of the high and low prices of shares of common stock of the Issuer on August 26, 2026). The transfer did not change the total number of shares of common stock of the Issuer of which the Reporting Person may be deemed to have beneficial ownership; however, the shares of common stock previously have been reported by the Reporting Person as indirectly owned. The Reporting Person believes that the transfer of shares from the trust constitutes a change in form of beneficial ownership of such shares, exempted by Rule 16a-13 under the Securities Exchange Act of 1934. Subsequently, on August 26, 2026, the Reporting Person transferred 7,769 shares of common stock of the Issuer from direct ownership to a trust. | SEC |
| 2025-11-03 | 2025-11-05 | Mcalevey Michael R | EVP & Chief Legal & Admin Off. | $3.1M | M — Option exercise | SEC |
| 2026-02-10 | 2026-02-12 | Foster Jon M | EVP and COO | $3.0M | F — Tax withholding (shares surrendered for taxes) | SEC |
| 2025-09-04 | 2025-09-08 | Cuffe Michael S. | EVP and Chief Clinical Officer | $2.9M | F — Tax withholding (shares surrendered for taxes) (scheduled 10b5-1)2 Form 4 footnotesF1 The exercise of stock appreciation rights and sale of shares reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 6, 2025. F2 Includes 2,595.9017 shares acquired under the Issuer's employee stock purchase plans. | SEC |
| 2026-02-05 | 2026-02-09 | Wyatt Christopher F. | SVP & Controller | $2.9M | F — Tax withholding (shares surrendered for taxes) | SEC |
The period balance: money in, money out
In the Form 4 filings submitted between Sep 8, 2025 and Aug 28, 2026 there is not one open-market purchase of HCA Healthcare, Inc.: 7 sales worth $32.7M and zero dollars bought.
Only codes P and S count, where an insider puts in or takes out their own money. A selling balance like HCA Healthcare, Inc.'s is the norm in the S&P 500, where much of the pay comes as stock. It is not a recommendation to buy or sell: it is what was filed.
Every transaction, code by code
| Code | What it means | Trades | Reported amount |
|---|---|---|---|
| A | Grant or award | 16 | $0 |
| F | Tax withholding (shares surrendered for taxes) | 15 | $73.1M |
| J | Other transaction (explained in the filing) | 14 | $4.4M |
| G | Gift | 7 | $0 |
| M | Option exercise | 7 | $22.7M |
| S | Open-market sale | 7 | $32.7M |
| Total | Everything filed in the period | 66 | $132.9M |
34 of the 66 rows carry no usable amount on the Form 4: they count as trades and add $0. The code labels come from the SEC index.
Who has traded
Over the 15 months of history, 20 distinct people or entities have filed HCA Healthcare, Inc. transactions: none bought on the open market and 5 sold. Counted by CIK, the fixed number the SEC gives each filer, and not by name, which each filer types their own way.
| Filer | Role | Transactions | Bought (count) | Sold (count) | Last filed |
|---|---|---|---|---|---|
| Hazen Samuel N | CEO | 10 | — | $21.5M (1) | 2026-02-12 |
| Berres Jennifer | SVP & Chief Human Res. Officer | 3 | — | $4.1M (1) | 2026-02-12 |
| Mcalevey Michael R | EVP & Chief Legal & Admin Off. | 9 | — | $2.7M (2) | 2026-08-28 |
| Cuffe Michael S. | EVP and Chief Clinical Officer | 7 | — | $2.4M (2) | 2026-02-12 |
| Wyatt Christopher F. | SVP & Controller | 5 | — | $2.0M (1) | 2026-02-12 |
| Marks Mike A | EVP and CFO | 7 | — | — | 2026-05-11 |
| Foster Jon M | EVP and COO | 4 | — | — | 2026-02-12 |
| Frist Thomas F Iii | Director | 3 | — | — | 2026-04-30 |
Shown here are the 8 who moved the most money, out of 20. The rest are in the full history, one link above. The name links to all their trades, in any company. "Transactions" counts any code; the money, open market only. Role: from their latest filing.
Month by month
By the month the trade was executed, not the month it was filed; months with no trades show zero. The busiest month was Feb 2026: 0 purchases and 5 sales, worth $29.3M. 12 of the 15 months have none.
| Month | Purchases | Amount | Sales | Amount |
|---|---|---|---|---|
| Aug 2025 | 0 | $0 | 0 | $0 |
| Sep 2025 | 0 | $0 | 1 | $1.6M |
| Oct 2025 | 0 | $0 | 0 | $0 |
| Nov 2025 | 0 | $0 | 1 | $1.8M |
| Dec 2025 | 0 | $0 | 0 | $0 |
| Jan 2026 | 0 | $0 | 0 | $0 |
| Feb 2026 | 0 | $0 | 5 | $29.3M |
| Mar 2026 | 0 | $0 | 0 | $0 |
| Apr 2026 | 0 | $0 | 0 | $0 |
| May 2026 | 0 | $0 | 0 | $0 |
| Jun 2026 | 0 | $0 | 0 | $0 |
| Jul 2026 | 0 | $0 | 0 | $0 |
| Aug 2026 | 0 | $0 | 0 | $0 |
| Sep 2026 | 0 | $0 | 0 | $0 |
| Oct 2026 | 0 | $0 | 0 | $0 |
The last month may be partial: a Form 4 is filed up to two business days later. The table does not say whether the pattern is good or bad; it says when it happened.
HCA Healthcare, Inc. (HCA) analysis page →
Other Healthcare companies with insider trades
All 500 are listed in the section index →
Which insiders are buying their own company stock →
How to read this data
1 of the 7 sales in the table are flagged as scheduled (10b5-1 plan): signed months ahead and executed automatically, so they say nothing about what the insider thinks today. HCA Healthcare has no open-market purchase (code P) in the history, the most common case in the S&P 500: insiders are already paid in stock. The latest filing is from Aug 28, 2026, and a Form 4 arrives up to two business days after the trade.
5 of the 20 rows in the table carry footnotes from the Form 4 itself, folded into the code column and copied verbatim; a row with no footnote means the filing has none. Code J on its own only says "other transaction": which one it is, if the filing explains it, is in its footnote.
Guide: Insider buying · all guides
What is behind these trades
The concepts on this page, explained from scratch in the Academy. Free, no account.
- What the efficiency hypothesis says and what it does NOT sayIf an insider's purchase is public and anyone can read it, is there any information left in it? That is the exact question that brings people here.
- Who really moves the market: the types of investorWho sits on the other side of each order, and where a company's own insiders fit among them.
- Supply, demand and price: why it rises and falls constantlyHow a piece of news ends up inside the price, and why the reaction to a filed sale is rarely the one you would expect.
Source: SEC EDGAR Form 4. This is a list of public facts, not financial advice or a recommendation to buy or sell.